RAD21 and SMC3 were found to be overexpressed in breast and prostate cancer and colon carcinoma (26–28), while SMC1A and RAD21 were found to be downregulated in acute myeloid leukemia and oral squamous cancer (29,30). Here, RAD21 is linked to Familial prostate cancer.